Your browser doesn't support javascript.
loading
Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.
Bao, Bin; Mitrea, Cristina; Wijesinghe, Priyanga; Marchetti, Luca; Girsch, Emily; Farr, Rebecca L; Boerner, Julie L; Mohammad, Ramzi; Dyson, Greg; Terlecky, Stanley R; Bollig-Fischer, Aliccia.
Afiliação
  • Bao B; Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
  • Mitrea C; Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
  • Wijesinghe P; Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
  • Marchetti L; The Microsoft Research - University of Trento Centre for Computational and Systems Biology, Rovereto, Italy.
  • Girsch E; Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
  • Farr RL; Department of Pharmacology, Wayne State University School of Medicine, Detroit MI 48201, USA.
  • Boerner JL; Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
  • Mohammad R; Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
  • Dyson G; Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Terlecky SR; Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
  • Bollig-Fischer A; Department of Pharmacology, Wayne State University School of Medicine, Detroit MI 48201, USA.
Sci Rep ; 7: 44125, 2017 03 10.
Article em En | MEDLINE | ID: mdl-28281569
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Neoplasias de Mama Triplo Negativas / Cloridrato de Erlotinib / Antioxidantes Limite: Female / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Neoplasias de Mama Triplo Negativas / Cloridrato de Erlotinib / Antioxidantes Limite: Female / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos